Cullinan Therapeutics offers a diversified portfolio with near-, mid-, and long-term value drivers, reducing dependence on external funding. Positive Phase 3 results for Zipalertinib and upcoming regulatory milestones could provide crucial funding to advance their autoimmune and oncology platforms. Additionally, CLN-049 and CLN-978 show promising clinical progress, positioning the company for multiple commercialization opportunities. Despite clinical risks and a premium valuation, Cullinan's broad pipeline and late-stage validation present an attractive risk-adjusted investment opportunity in immune-reset biotech.
IREN Limited is set to report earnings showing a significant revenue drop from $187.3 million to around $132-142 million year-over-year, with an expected loss per share of approximately -$0.55 compared to last year's profit. The company faces challen...
Real REMAX Group finalized its acquisition of RE/MAX Holdings on August 24, 2026, forming a combined company with over 180,000 agents worldwide. The new entity trades on Nasdaq under the ticker REAX and blends Real's technology platform with RE/MAX's...
Build-A-Bear Workshop reported Q2 earnings per share of $0.70, beating analyst estimates despite a decline from $0.94 last year. However, revenue fell 7.2% year-over-year to $115.29 million, missing expectations and leading to a lowered annual sales ...
Affirm Holdings, a leader in buy now, pay later services, is set to report strong Q2 earnings with an expected EPS of $0.35 and revenue of $1.11 billion, up 26.2% year-over-year. Growth is driven by a 29.3% increase in Gross Merchandise Volume and a ...
Amphenol Corporation plans a 2-for-1 stock split on September 3, 2026, doubling shares while keeping investment value steady. The company shows strong growth, especially in its Communications Solutions segment, driven by AI-related IT demand and acqu...
